Keywords: USA, FDA, Mylan, Merck & Co, Hyzaar, Cozaar, Waatson, Lotel, Novartis, Endo, Opana ER, Pay-to-delay

US FDA clears Mylan’s generic versions of Hyzaar and Cozaar and Watson’s copy of Lotrel; Watson settles with Endo

Article | 18 October 2010

Print This

US drugmaker Mylan (Nasdaq: MYL) has received final approvals from the US Food and Drug Administration for its Abbreviated New ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in